Europe — EMA
Mitoxantrona Accord (Mitoxantrone)
GNH USA supplies Mitoxantrona Accord (Mitoxantrone), a anthracenedione for acute myeloid leukemia, prostate cancer, breast cancer and non-Hodgkin lymphoma.
Request sourcing
What is Mitoxantrone?
Mitoxantrone, the active ingredient in Mitoxantrona Accord, is a anthracenedione presented as a solution for injection for intravenous use. It treats acute myeloid leukemia, prostate cancer, breast cancer, and non-Hodgkin lymphoma in adult patients.
GNH USA supplies Mitoxantrona Accord as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide.
What is Mitoxantrone used for?
Mitoxantrone is used in the treatment of hematologic malignancies and solid tumours.
Acute Myeloid Leukemia: induces remission by causing DNA strand breaks in leukemic cells. Prostate Cancer: reduces tumour burden in advanced disease settings. Breast Cancer: employed in combination regimens for metastatic disease control. Non-Hodgkin Lymphoma: contributes to disease control in refractory or relapsed cases.
What are the side effects of Mitoxantrone?
Mitoxantrone may cause a range of adverse reactions.
Common Side Effects: - Nausea and vomiting - Fatigue or weakness - Alopecia (hair loss) - Myelosuppression (low blood cell counts) - Mucositis (mouth inflammation)
Serious or Rare Side Effects: - Cardiotoxicity, including reduced left‑ventricular function - Severe infections due to neutropenia - Secondary acute leukaemia or myelodysplastic syndrome
What precautions apply to Mitoxantrone?
Mitoxantrone requires careful monitoring before and during therapy.
Monitor cardiac function: assess baseline ejection fraction and repeat periodically. Assess liver function: adjust use in patients with hepatic impairment. Evaluate renal function: consider dose modification for severe renal insufficiency. Avoid in patients with known hypersensitivity to anthracenediones. Use effective contraception: potential teratogenic risk. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.
What does Mitoxantrone interact with?
Mitoxantrone can interact with several drug classes.
Major Interactions (Avoid): - Concurrent anthracyclines or other topoisomerase II inhibitors: additive bone‑marrow suppression. - Live vaccines: increased risk of severe infection. - Radiopharmaceuticals: heightened systemic toxicity.
Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin): may reduce plasma concentrations. - Anticoagulants (e.g., warfarin): may increase bleeding tendency. - Nephrotoxic agents (e.g., cisplatin): require renal function monitoring.
